Glycophos (sodium glycerophosphate)
Phosphates Intravenous Vial (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: sodium glycerophosphate
Drug class: Phosphates
Therapeutic class: Electrolyte Balance-Nutritional Products
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Glycophos
Indications
The following indications are listed for Glycophos:
- Hypophosphatemia
Also known as: Abnormally Decreased Blood Phosphate Level.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Phosphate Supplements;Urine Ph Modifiers/Phosphate Reducers
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Lanthanum and sevelamer bind to phosphate.(1-2) Tenapanor is a sodium/hydrogen exchanger 3 (NHE3) inhibitor.(3) All three agents are used to lower phosphate absorption in the body.(1-3)
CLINICAL EFFECTS: Concurrent use of phosphate supplements or urinary pH modifiers high in phosphate with agents that reduce serum phosphorus may decrease the effectiveness of both agents.
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: Patients should normally not receive phosphate supplements or urinary pH modifiers high in phosphate concurrently with agents that reduce serum phosphorus.
DISCUSSION: Lanthanum, sevelamer, and tenapanor are indicated to control phosphorus levels. Consider discontinuing or holding phosphate supplements and urinary pH modifiers high in phosphate in patients receiving these agents.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Hypernatremia
- Hyperphosphatemia
- Hypocalcemia
- Chronic heart failure
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Edema
- Hepatic cirrhosis
- Kidney disease with likely reduction in glomerular filtration rate (GFr)
- Severe hepatic disease
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Hyperphosphatemia
- Hypocalcemia
- Hypocalcemic tetany
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Hypophosphatemia | ||
| E83.31 | ICD10CM | Familial hypophosphatemia |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.